Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
ApexOnco Front Page
Recent articles
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
But more detail is awaited, especially on toxicity.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
The ESMO regular abstract lift reveals first human datasets for several projects.
